Какова цена за Fresh Tracks Therapeutics, Inc. (FRTX)

Цена за Fresh Tracks Therapeutics, Inc. (FRTX) Это $0.94

Какова рыночная капитализация для Fresh Tracks Therapeutics, Inc. (FRTX)

Рыночная капитализация для Fresh Tracks Therapeutics, Inc. (FRTX) Это $2.73M

Прибыль Fresh Tracks Therapeutics, Inc. (FRTX)

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Год	Прибыль	Изменить
2026 (TTM)	$-5.89M	3.46%
2023	$-5.69M	-73.02%
2022	$-21.10M	-46.54%
2021	$-39.47M	88.75%
2020	$-20.91M	-12.41%
2019	$-23.88M	46.90%
2018	$-16.25M	25.42%
2017	$-12.96M	44.43%
2016	$-8.97M	-2.87%
2015	$-9.24M	-43.98%
2014	$-16.49M	-47.21%
2013	$-31.24M	36.42%
2012	$-22.90M	214.42%
2011	$-7.28M	-76.03%
2010	$-30.39M	6.40%
2009	$-28.56M	-22.56%
2008	$-36.88M	3.01%
2007	$-35.80M	56.49%
2006	$-22.88M	0.00%
2005	0.00	0.00%
2004	0.00	-100.00%
2003	$-26.59M	-25.80%
2002	$-35.83M	0.00%
2001	0.00	0.00%
2000	0.00	0.00%

Год

Прибыль

Изменить

2026 (TTM)

$-5.89M

3.46%

2023

$-5.69M

-73.02%

2022

$-21.10M

-46.54%

2021

$-39.47M

88.75%

2020

$-20.91M

-12.41%

2019

$-23.88M

46.90%

2018

$-16.25M

25.42%

2017

$-12.96M

44.43%

2016

$-8.97M

-2.87%

2015

$-9.24M

-43.98%

2014

$-16.49M

-47.21%

2013

$-31.24M

36.42%

2012

$-22.90M

214.42%

2011

$-7.28M

-76.03%

2010

$-30.39M

6.40%

2009

$-28.56M

-22.56%

2008

$-36.88M

3.01%

2007

$-35.80M

56.49%

2006

$-22.88M

0.00%

2005

0.00

0.00%

2004

0.00

-100.00%

2003

$-26.59M

-25.80%

2002

$-35.83M

0.00%

2001

0.00

0.00%

2000

0.00

0.00%

Компания	Прибыль	Разница в прибыли	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-89,641.67%	US
Argenx SE ARGX.US	$1.95B	-33,212.38%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-51,122.19%	BE

Компания

Прибыль

Разница в прибыли

Страна